Diffusion Pharmaceuticals Receives FDA Orphan Designation for TSC, a First-in-Class Drug for the Treatment of Metastatic Brain Cancer
12/11/2012 10:16:26 AM
More...
|
Diffusion Pharmaceuticals Successfully Completes Phase I Brain Cancer Trial
11/20/2012 9:44:29 AM
More...
|
Diffusion Pharmaceuticals Closes on $5 Million Financing; Continues Phase 2 Clinical Trial In Primary Brain Cancer
9/17/2012 10:20:25 AM
More...
|
New Patents Issued to Diffusion Pharmaceuticals
8/16/2012 9:41:02 AM
More...
|
Diffusion Pharmaceuticals Successfully Completes First Cohort in Multicenter Phase I/II Brain Cancer Trial of TSC
8/2/2012 10:39:58 AM
More...
|
Diffusion Pharmaceuticals Receives FDA Orphan Status for TSC, a First-in-Class Drug for the Treatment of Primary Brain Cancer
7/26/2011 9:24:21 AM
More...
|
Diffusion Pharmaceuticals Achieves Positive Results in Phase I/II Clinical Trial of Trans Sodium Crocetinate in Peripheral Artery Disease
11/16/2010 11:41:04 AM
More...
|
Results of Phase I/II Clinical Trial of Diffusion Pharmaceuticals' Trans Sodium Crocetinate in Patients with Peripheral Artery Disease (PAD) to be Presented at American Heart Association Scientific Sessions
11/15/2010 12:14:57 PM
More...
|
Results of Phase I/II Clinical Trial of Diffusion Pharmaceuticals' Trans Sodium Crocetinate in Patients with Peripheral Artery Disease (PAD) to be Presented at American Heart Association Scientific Sessions
11/10/2010 11:36:39 AM
More...
|
Diffusion Pharmaceuticals Announces Issuance of New U.S. Patent
8/2/2010 9:13:43 AM
More...
|
|